LON:CTEC - ConvaTec Group Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: GBX 205.80
  • Forecasted Upside: -16.78 %
  • Number of Analysts: 8
  • Breakdown:
  • 2 Sell Ratings
  • 5 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
GBX 247.30
▼ -0.4 (-0.16%)
1 month | 3 months | 12 months
Get New ConvaTec Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CTEC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CTEC

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
GBX 205.80
▼ -16.78% Downside Potential
This price target is based on 8 analysts offering 12 month price targets for ConvaTec Group in the last 3 months. The average price target is GBX 205.80, with a high forecast of GBX 230 and a low forecast of GBX 176. The average price target represents a -16.78% upside from the last price of GBX 247.30.

Hold

The current consensus among 8 investment analysts is to hold stock in ConvaTec Group. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 3 sell ratings
12/22/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 3 sell ratings
3/21/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 4 sell ratings
6/19/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 3 sell ratings
9/17/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 3 sell ratings
12/16/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 3 sell ratings
3/16/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 2 sell ratings
5/15/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 2 sell ratings
6/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/1/2021Royal Bank of CanadaBoost Price TargetSector PerformGBX 200 ➝ GBX 230
i
5/11/2021Shore CapitalReiterated RatingBuy
i
4/29/2021Shore CapitalReiterated RatingBuy
i
3/11/2021Shore CapitalReiterated RatingBuy
i
11/2/2020Shore CapitalReiterated RatingHold
i
10/29/2020Credit Suisse GroupBoost Price TargetUnderperformGBX 185 ➝ GBX 190
i
10/29/2020JPMorgan Chase & Co.Boost Price TargetUnderweightGBX 175 ➝ GBX 176
i
9/29/2020Royal Bank of CanadaDowngradeSector PerformGBX 245 ➝ GBX 200
i
7/22/2020BarclaysReiterated RatingEqual weight
i
7/8/2020BarclaysReiterated RatingEqual weight
i
7/2/2020Morgan StanleyBoost Price TargetEqual weightGBX 206 ➝ GBX 208
i
7/2/2020Peel HuntReiterated RatingAdd
i
6/30/2020JPMorgan Chase & Co.Boost Price TargetUnderweightGBX 167 ➝ GBX 172
i
6/26/2020Peel HuntDowngradeAddGBX 220 ➝ GBX 225
i
6/18/2020CitigroupReiterated RatingNeutral
i
6/10/2020Royal Bank of CanadaUpgradeOutperformGBX 178 ➝ GBX 245
i
6/3/2020Peel HuntReiterated RatingBuy
i
5/20/2020Jefferies Financial GroupLower Price TargetBuyGBX 250 ➝ GBX 240
i
5/18/2020BarclaysBoost Price TargetEqual WeightGBX 182 ➝ GBX 190
i
5/1/2020CSFBBoost Price TargetUnderperformGBX 175 ➝ GBX 180
i
5/1/2020JPMorgan Chase & Co.Boost Price TargetUnderweightGBX 160 ➝ GBX 167
i
5/1/2020Credit Suisse GroupBoost Price TargetUnderperformGBX 175 ➝ GBX 180
i
5/1/2020UBS GroupBoost Price TargetBuyGBX 235 ➝ GBX 245
i
4/30/2020Shore CapitalReiterated RatingHold
i
4/30/2020Peel HuntReiterated RatingBuy
i
4/24/2020Peel HuntReiterated RatingBuy
i
4/7/2020Peel HuntReiterated RatingBuy
i
4/1/2020JPMorgan Chase & Co.Lower Price TargetUnderweightGBX 177 ➝ GBX 160
i
3/30/2020Peel HuntReiterated RatingBuy
i
3/20/2020Royal Bank of CanadaLower Price TargetSector PerformerGBX 197 ➝ GBX 178
i
3/19/2020Peel HuntReiterated RatingBuy
i
3/12/2020Peel HuntLower Price TargetBuyGBX 250 ➝ GBX 220
i
3/5/2020Peel HuntReiterated RatingBuy
i
3/2/2020UBS GroupReiterated RatingBuy
i
3/2/2020JPMorgan Chase & Co.Boost Price TargetUnderweightGBX 168 ➝ GBX 177
i
2/24/2020Peel HuntReiterated RatingBuy
i
2/21/2020UBS GroupReiterated RatingBuy
i
2/18/2020BarclaysLower Price TargetEqual weightGBX 185 ➝ GBX 182
i
2/13/2020Peel HuntReiterated RatingBuy
i
2/5/2020Peel HuntReiterated RatingBuy
i
2/4/2020JPMorgan Chase & Co.Reiterated RatingUnderweightGBX 168
i
2/3/2020BarclaysReiterated RatingEqual weight
i
1/27/2020Peel HuntReiterated RatingBuy
i
1/23/2020Shore CapitalDowngradeHold
i
1/21/2020Jefferies Financial GroupBoost Price TargetBuyGBX 220 ➝ GBX 250
i
1/20/2020JPMorgan Chase & Co.DowngradeUnderweightGBX 171 ➝ GBX 168
i
1/10/2020UBS GroupUpgradeBuyGBX 185 ➝ GBX 235
i
1/7/2020Peel HuntReiterated RatingBuy
i
1/7/2020BarclaysReiterated RatingEqual weight
i
12/9/2019Royal Bank of CanadaDowngradeSector PerformerGBX 210 ➝ GBX 197
i
12/5/2019Peel HuntReiterated RatingBuy
i
11/29/2019Jefferies Financial GroupBoost Price TargetBuyGBX 145 ➝ GBX 220
i
11/22/2019Shore CapitalReiterated RatingBuy
i
11/4/2019Peel HuntReiterated RatingBuy
i
11/1/2019BarclaysBoost Price TargetEqual weightGBX 130 ➝ GBX 185
i
10/31/2019JPMorgan Chase & Co.Reiterated RatingNeutralGBX 174 ➝ GBX 171
i
10/30/2019The Goldman Sachs GroupBoost Price TargetNeutralGBX 118 ➝ GBX 183
i
10/28/2019UBS GroupReiterated RatingNeutral
i
10/25/2019Peel HuntReiterated RatingBuyGBX 280
i
10/25/2019Peel HuntReiterated RatingBuyGBX 280
i
10/17/2019Credit Suisse GroupDowngradeUnderperform
i
10/7/2019Peel HuntReiterated RatingBuy
i
9/18/2019Peel HuntReiterated RatingBuyGBX 280
i
9/18/2019Peel HuntReiterated RatingBuyGBX 280
i
9/2/2019Peel HuntReiterated RatingBuy
i
8/19/2019Peel HuntReiterated RatingBuy
i
8/12/2019Peel HuntBoost Price TargetBuyGBX 230 ➝ GBX 280
i
8/6/2019UBS GroupBoost Price TargetNeutralGBX 129 ➝ GBX 185
i
8/5/2019JPMorgan Chase & Co.Boost Price TargetNeutralGBX 132 ➝ GBX 174
i
7/29/2019UBS GroupBoost Price TargetNeutralGBX 120 ➝ GBX 129
i
7/29/2019Peel HuntReiterated RatingBuy
i
7/22/2019Peel HuntReiterated RatingBuy
i
7/12/2019Deutsche Bank AktiengesellschaftReiterated RatingSell
i
7/11/2019Peel HuntReiterated RatingBuy
i
7/3/2019Peel HuntReiterated RatingBuy
i
6/4/2019Peel HuntReiterated RatingBuy
i
5/9/2019JPMorgan Chase & Co.Reiterated RatingNeutralGBX 135 ➝ GBX 132
i
5/3/2019Jefferies Financial GroupReiterated RatingBuyGBX 145
i
5/3/2019Numis SecuritiesReiterated RatingBuyGBX 200
i
5/2/2019Deutsche Bank AktiengesellschaftLower Price TargetSellGBX 130 ➝ GBX 113
i
5/2/2019Peel HuntReiterated RatingBuy
i
4/30/2019CitigroupInitiated CoverageNeutralGBX 138
i
4/17/2019BarclaysReiterated RatingEqual WeightGBX 148 ➝ GBX 130
i
4/2/2019Peel HuntReiterated RatingBuy
i
3/25/2019Peel HuntUpgradeBuyGBX 150 ➝ GBX 230
i
3/12/2019Peel HuntReiterated RatingHold
i
2/19/2019The Goldman Sachs GroupLower Price TargetNeutralGBX 160 ➝ GBX 118
i
2/19/2019UBS GroupLower Price TargetNeutralGBX 150 ➝ GBX 120
i
2/18/2019JPMorgan Chase & Co.Reiterated RatingNeutralGBX 192 ➝ GBX 135
i
2/14/2019Peel HuntReiterated RatingHoldGBX 170 ➝ GBX 150
i
2/8/2019BarclaysLower Price TargetUnderweightGBX 150 ➝ GBX 148
i
2/1/2019Peel HuntReiterated RatingHold
i
1/21/2019Numis SecuritiesReiterated RatingBuyGBX 220
i
1/18/2019The Goldman Sachs GroupLower Price TargetNeutralGBX 165 ➝ GBX 160
i
1/4/2019Peel HuntReiterated RatingHold
i
1/2/2019JPMorgan Chase & Co.Reiterated RatingNeutral
i
12/10/2018Deutsche Bank AktiengesellschaftLower Price TargetSellGBX 180 ➝ GBX 130
i
12/6/2018Peel HuntReiterated RatingHold
i
11/27/2018BarclaysInitiated CoverageUnderweightGBX 150
i
11/1/2018Peel HuntReiterated RatingHold
i
10/31/2018Jefferies Financial GroupLower Price TargetBuyGBX 280 ➝ GBX 210
i
10/26/2018UBS GroupDowngradeNeutralGBX 250 ➝ GBX 150
i
10/25/2018Peel HuntLower Price TargetHoldGBX 220 ➝ GBX 170
i
10/16/2018JPMorgan Chase & Co.DowngradeNeutralGBX 280 ➝ GBX 183
i
10/15/2018Royal Bank of CanadaLower Price TargetOutperformGBX 240 ➝ GBX 210
i
10/15/2018Numis SecuritiesReiterated RatingHoldGBX 220
i
10/15/2018Peel HuntReiterated RatingHold
i
10/5/2018Deutsche Bank AktiengesellschaftReiterated RatingSell
i
10/3/2018Peel HuntReiterated RatingHold
i
9/4/2018Peel HuntReiterated RatingHold
i
8/8/2018Royal Bank of CanadaReiterated RatingOutperformGBX 240
i
8/3/2018Deutsche Bank AktiengesellschaftReiterated RatingSell
i
8/2/2018Numis SecuritiesReiterated RatingHold
i
8/1/2018Peel HuntReiterated RatingHoldGBX 210 ➝ GBX 220
i
7/4/2018Deutsche Bank AktiengesellschaftReiterated RatingSell
i
7/3/2018Peel HuntReiterated RatingHold
i
5/3/2018Credit Suisse GroupBoost Price TargetNeutralGBX 215 ➝ GBX 225
i
5/3/2018Deutsche Bank AktiengesellschaftReiterated RatingSell
i
5/2/2018Numis SecuritiesReiterated RatingHoldGBX 180
i
5/2/2018Peel HuntReiterated RatingHoldGBX 210
i
4/25/2018Credit Suisse GroupReiterated RatingNeutralGBX 215
i
4/24/2018Deutsche Bank AktiengesellschaftReiterated RatingSell
i
4/4/2018Peel HuntReiterated RatingHold
i
3/26/2018HSBCUpgradeBuyGBX 240 ➝ GBX 238
i
3/22/2018Royal Bank of CanadaUpgradeOutperformGBX 260 ➝ GBX 240
i
3/2/2018Peel HuntReiterated RatingHoldGBX 210
i
3/2/2018Numis SecuritiesReiterated RatingHoldGBX 180
i
2/23/2018Morgan StanleyReiterated RatingOverweightGBX 249
i
2/16/2018CitigroupReiterated RatingNeutralGBX 226
i
2/15/2018Credit Suisse GroupLower Price TargetNeutralGBX 225 ➝ GBX 215
i
2/15/2018Peel HuntReiterated RatingHoldGBX 250
i
2/15/2018Numis SecuritiesReiterated RatingHoldGBX 180
i
2/7/2018Numis SecuritiesUpgradeHoldGBX 180
i
2/1/2018Peel HuntReiterated RatingHoldGBX 250
i
12/5/2017Numis SecuritiesReiterated RatingReduceGBX 180
i
12/1/2017Deutsche Bank AktiengesellschaftReiterated RatingSellGBX 180
i
10/31/2017Peel HuntReiterated RatingHoldGBX 250
i
10/18/2017Numis SecuritiesUpgradeReduceGBX 180
i
10/17/2017Credit Suisse GroupLower Price TargetNeutralGBX 280 ➝ GBX 225
i
10/17/2017Peel HuntDowngradeHoldGBX 390 ➝ GBX 250
i
10/17/2017CitigroupLower Price TargetNeutralGBX 290 ➝ GBX 226
i
10/16/2017Numis SecuritiesDowngradeSellGBX 220
i
10/11/2017CitigroupReiterated RatingNeutralGBX 290
i
9/20/2017JPMorgan Chase & Co.Reiterated RatingOverweightGBX 303
i
9/11/2017The Goldman Sachs GroupReiterated RatingBuyGBX 330
i
8/21/2017Deutsche Bank AktiengesellschaftBoost Price TargetBuyGBX 330 ➝ GBX 335
i
8/9/2017Peel HuntBoost Price TargetBuyGBX 380 ➝ GBX 390
i
8/9/2017Numis SecuritiesLower Price TargetReduceGBX 260 ➝ GBX 250
i
8/6/2017Deutsche Bank AktiengesellschaftReiterated RatingBuyGBX 330
i
8/4/2017JPMorgan Chase & Co.Lower Price TargetOverweightGBX 318 ➝ GBX 303
i
8/3/2017Numis SecuritiesReiterated RatingReduceGBX 260
i
8/3/2017The Goldman Sachs GroupReiterated RatingBuyGBX 340
i
8/3/2017Peel HuntReiterated RatingBuyGBX 380
i
7/31/2017Deutsche Bank AktiengesellschaftReiterated RatingBuyGBX 330
i
7/20/2017Peel HuntReiterated RatingBuyGBX 380
i
7/11/2017Numis SecuritiesDowngradeReduceGBX 276 ➝ GBX 260
i
6/30/2017The Goldman Sachs GroupReiterated RatingBuyGBX 340
i
5/15/2017Deutsche Bank AktiengesellschaftReiterated RatingBuyGBX 330
i
5/8/2017Deutsche Bank AktiengesellschaftReiterated RatingBuyGBX 330
i
5/5/2017JPMorgan Chase & Co.Boost Price TargetOverweightGBX 305 ➝ GBX 318
i
5/5/2017Credit Suisse GroupBoost Price TargetNeutralGBX 275 ➝ GBX 290
i
5/4/2017Numis SecuritiesReiterated RatingHoldGBX 276
i
5/4/2017Morgan StanleyReiterated RatingEqual weight
i
5/4/2017The Goldman Sachs GroupReiterated RatingBuyGBX 310
i
5/4/2017Peel HuntBoost Price TargetBuyGBX 300 ➝ GBX 380
i
4/4/2017Numis SecuritiesReiterated RatingHoldGBX 276
i
3/30/2017JPMorgan Chase & Co.Reiterated RatingOverweightGBX 305
i
3/23/2017Royal Bank of CanadaBoost Price Targetsector performGBX 242 ➝ GBX 278
i
3/21/2017The Goldman Sachs GroupReiterated RatingBuyGBX 310
i
3/7/2017The Goldman Sachs GroupBoost Price TargetBuyGBX 300 ➝ GBX 310
i
3/6/2017Deutsche Bank AktiengesellschaftBoost Price TargetBuyGBX 275 ➝ GBX 300
i
3/3/2017JPMorgan Chase & Co.Boost Price TargetOverweightGBX 271 ➝ GBX 305
i
3/3/2017Credit Suisse GroupBoost Price TargetNeutralGBX 250 ➝ GBX 275
i
3/2/2017Peel HuntReiterated RatingBuyGBX 300
i
2/27/2017Deutsche Bank AktiengesellschaftReiterated RatingBuy
i
2/24/2017Peel HuntReiterated RatingBuyGBX 300
i
1/4/2017JPMorgan Chase & Co.Reiterated RatingOverweightGBX 271
i
12/6/2016Credit Suisse GroupReiterated RatingNeutralGBX 250
i
12/6/2016UBS GroupReiterated RatingBuyGBX 300
i
12/6/2016The Goldman Sachs GroupReiterated RatingBuyGBX 270
i
12/6/2016JPMorgan Chase & Co.Initiated CoverageOverweightGBX 271
i
12/6/2016Peel HuntInitiated CoverageBuyGBX 300
i
12/5/2016Deutsche Bank AktiengesellschaftInitiated CoverageBuyGBX 275
i
(Data available from 6/14/2016 forward)
ConvaTec Group logo
ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes. The company also provides devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes. In addition, it offers continence and critical care products, including intermittent urological catheters; and products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders, as well as devices and products use in intensive care units and hospital settings. Further, the company provides advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and various disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, suction handles and tubes, gastroenterology tubes, and securement devices. Additionally, it offers disposable infusion sets to the manufacturers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and various products to hospitals and the home healthcare sector. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. The company was founded in 1978 and is headquartered in Reading, the United Kingdom.
Read More

Today's Range

Now: GBX 247.30
246.50
250.40

50 Day Range

MA: GBX 221.30
193.80
249.30

52 Week Range

Now: GBX 247.30
173.20
250.40

Volume

88,619 shs

Average Volume

3,208,940 shs

Market Capitalization

£4.98 billion

P/E Ratio

61.83

Dividend Yield

1.68%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of ConvaTec Group?

The following equities research analysts have issued reports on ConvaTec Group in the last year: Barclays PLC, Citigroup Inc., Credit Suisse Group AG, JPMorgan Chase & Co., Morgan Stanley, Peel Hunt, Royal Bank of Canada, and Shore Capital.
View the latest analyst ratings for CTEC.

What is the current price target for ConvaTec Group?

5 Wall Street analysts have set twelve-month price targets for ConvaTec Group in the last year. Their average twelve-month price target is GBX 205.80, suggesting a possible downside of 16.8%. Royal Bank of Canada has the highest price target set, predicting CTEC will reach GBX 230 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of GBX 176 for ConvaTec Group in the next year.
View the latest price targets for CTEC.

What is the current consensus analyst rating for ConvaTec Group?

ConvaTec Group currently has 2 sell ratings, 5 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CTEC, but not buy more shares or sell existing shares.
View the latest ratings for CTEC.

What other companies compete with ConvaTec Group?

How do I contact ConvaTec Group's investor relations team?

ConvaTec Group's physical mailing address is 3 Forbury Place Floor 7, 23 Forbury Road, ICKENHAM, RG1 3JH, United Kingdom. The company's listed phone number is 44 11 8952 8100. The official website for ConvaTec Group is www.convatecgroup.com.